Rabies vaccine prepared in human cell cultures: progress and perspectives.
Rabies vaccine prepared in human diploid cell strains is a replacement for the previously available vaccines that are prepared in animal tissues and are less immunogenic and more reactogenic. The human cel-grown vaccine made in the United States is a split-product vaccine, whereas the vaccines made in Europe are whole-virion vaccines. Both types of vaccine contain concentrated and inactivated "fixed" rabies virus. When used before exposure to rabies virus, the vaccine should be given intramuscularly in three 1-ml doses on days 0, 7, and 21. Immediately after exposure to rabies virus, a person should be given human rabies immune globulin (20 international units/kg). This treatment should be followed by five intramuscular doses of vaccine given on days 0, 3, 7, 14, and 28. For maintenance of long-term immunity in persons continously exposed to the risk of rabies, booster doses of the vaccine should be given at two-year intervals.
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D005455:Fluorescent Antibody Technique; D006023:Glycoproteins; D006801:Humans; D007111:Immunity, Cellular; D007117:Immunization, Secondary; D007136:Immunoglobulins; D007372:Interferons / Q000627:therapeutic use; D051379:Mice; D008828:Microbiological Techniques; D009500:Neutralization Tests; D011817:Rabbits; D011819:Rabies Vaccines / Q000008:administration & dosage; D011820:Rabies virus / Q000254:growth & development* / Q000648:ultrastructure; D010948:Viral Plaque Assay
D000914:Antibodies, Viral; D006023:Glycoproteins; D007136:Immunoglobulins; D011819:Rabies Vaccines; D007372:Interferons